Hypertension, a common chronic disease, is associated with cognitive impairment. Cognitive impairment, especially Alzheimer’s disease (AD), seriously affects older adults’ quality of life and aggravates the burden of disease on society and families. Elevated Alzheimer-associated neuronal thread protein (AD7c-NTP) has been observed in the urine of patients with AD and mild cognitive impairment; however, it is not clear whether this protein can be used as a biomarker for cognitive impairment in older hypertensive patients.
Objective:
To explore the value of urinary AD7c-NTP, and the association of urinary AD7c-NTP with cognitive function in older hypertensive patients.
Methods:
This was a cross-sectional study. In total, 134 hypertensive patients aged ≥60 years were divided into two groups: Lower Cognitive Function group (LCF group, n = 89) and Normal Control group (NC group, n = 45) based on the Montreal Cognitive Assessment (MoCA). Urinary AD7c-NTP, blood glucose, serum insulin, superoxide dismutase (SOD) and malondialdehyde (MDA) levels were measured.
Results:
Urinary AD7c-NTP level was significantly higher in the LCF group than in the NC group [0.48 (0.21–1.00) versus 0.25 (0.04–0.44) ng/ml, p < 0.001]. The LCF group had lower SOD level [(43.07±23.74) versus (53.12±25.80) U/ml, p = 0.026] and higher homeostasis model assessment of insulin resistance (HOMA-IR) [7.17 (3.74–13.94) versus 6.01 (3.78–7.43), p = 0.033] than the NC group. Urinary AD7c-NTP level was associated with MoCA score and HOMA-IR but not with SOD, MDA, blood glucose, and insulin.
Conclusion:
The level of urinary AD7c-NTP is elevated in older hypertensive patients with lower cognitive function, and insulin resistance may be involved in the process.
WangJ, ZhangL, WangF, LiuL, WangH, China National Survey of Chronic Kidney Disease Working Group (2014) Prevalence, awareness, treatment, and control of hypertension in China: Results from a national survey. Am J Hypertens27, 1355–1361.
2.
Bermejo-ParejaF, Benito-LeonJ, LouisED, TrincadoR, CarroE, VillarejoA, de la CamaraAG (2010) Risk of incident dementia in drug-untreated arterial hypertension: A population-based study. J Alzheimers Dis22, 949–958.
3.
QiuC, WinbladB, FratiglioniL (2005) The age-dependent relation of blood pressure to cognitive function and dementia. Lancet Neurol4, 487–499.
4.
ButterfieldDA, SwomleyAM, SultanaR (2013) Amyloid beta-peptide (1-42)-induced oxidative stress in Alzheimer disease: Importance in disease pathogenesis and progression. Antioxid Redox Signal19, 823–835.
5.
IadecolaC (2013) The pathobiology of vascular dementia. Neuron80, 844–866.
6.
FaracoG, IadecolaC (2013) Hypertension: A harbinger of stroke and dementia. Hypertension62, 810–817.
7.
GottesmanRF, AlbertMS, AlonsoA, CokerLH, CoreshJ, DavisSM, DealJA, McKhannGM, MosleyTH, SharrettAR, SchneiderALC, WindhamBG, WruckLM, KnopmanDS (2017) Associations between midlife vascular risk factors and 25-year incident dementia in the Atherosclerosis Risk in Communities (ARIC) Cohort. JAMA Neurol74, 1246–1254.
8.
HasnainM, ViewegWV (2014) Possible role of vascular risk factors in Alzheimer’s disease and vascular dementia. Curr Pharm Des20, 6007–6013.
HatanakaH, HanyuH, HiroseD, FukusawaR, NamiokaN, IwamotoT (2015) Peripheral oxidative stress markers in individuals with Alzheimer’s disease with or without cerebrovascular disease. J Am Geriatr Soc63, 1472–1474.
11.
KangIG, JungJH, KimST (2013) The effect of obstructive sleep apnea on DNA damage and oxidative stress. Clin Exp Otorhinolaryngol6, 68–72.
12.
ChengG, HuangC, DengH, WangH (2012) Diabetes as a risk factor for dementia and mild cognitive impairment: A meta-analysis of longitudinal studies. Intern Med J42, 484–491.
13.
MarksJL, PorteDJr, StahlWL, BaskinDG (1990) Localization of insulin receptor mRNA in rat brain by in situ hybridization. Endocrinology127, 3234–3236.
14.
de la MonteSM, ChenGJ, RiveraE, WandsJR (2003) Neuronal thread protein regulation and interaction with microtubule-associated proteins in SH-Sy5y neuronal cells. Cell Mol Life Sci60, 2679–2691.
15.
de La MonteSM, CarlsonRI, BrownNV, WandsJR (1996) Profiles of neuronal thread protein expression in Alzheimer’s disease. J Neuropathol Exp Neurol55, 1038–1050.
16.
YounYC, ParkKW, HanSH, KimS (2011) Urine neural thread protein measurements in Alzheimer disease. J Am Med Dir Assoc12, 372–376.
17.
MaL, ChenJ, WangR, HanY, ZhangJ, DongW, ZhangX, WuY, ZhaoZ (2015) The level of Alzheimer-associated neuronal thread protein in urine may be an important biomarker of mild cognitive impairment. J Clin Neurosci22, 649–652.
18.
LiuLS (2011) [2010 Chinese guidelines for the management of hypertension]. Zhonghua Xin Xue Guan Bing Za Zhi39, 579–615.
19.
NasreddineZS, PhillipsNA, BedirianV, CharbonneauS, WhiteheadV, CollinI, CummingsJL, ChertkowH (2005) The Montreal Cognitive Assessment, MoCA: A brief screening tool for mild cognitive impairment. J Am Geriatr Soc53, 695–699.
20.
MaL, ChenJ, WangR, HanY, ZhangJ, DongW, ZhaoZ, LiuY, ChuX (2014) Alzheimer-associated urine neuronal thread protein level increases with age in a healthy Chinese population. J Clin Neurosci21, 2118–2121.
21.
De La MonteSM, WandsJR (2001) The AD7c-NTP neuronal thread protein biomarker for detecting Alzheimer’s disease. J Alzheimers Dis3, 345–353.
22.
GhanbariH, GhanbariK, BeheshtiI, MunzarM, VasauskasA, AverbackP (1998) Biochemical assay for AD7C-NTP in urine as an Alzheimer’s disease marker. J Clin Lab Anal12, 285–288.
23.
MonteSM, GhanbariK, FreyWH, BeheshtiI, AverbackP, HauserSL, GhanbariHA, WandsJR (1997) Characterization of the AD7C-NTP cDNA expression in Alzheimer’s disease and measurement of a 41-kD protein in cerebrospinal fluid. J Clin Invest100, 3093–3104.
24.
de la MonteSM, WandsJR (2001) Neurodegeneration changes in primary central nervous system neurons transfected with the Alzheimer-associated neuronal thread protein gene. Cell Mol Life Sci58, 844–849.
25.
JinH, GuanS, WangR, FangX, LiuH, WuY, ZhangY, LiuC (2018) The distribution of urinary Alzheimer-associated neuronal thread protein and its association with common chronic diseases in the general population. J Alzheimers Dis65, 433–442.
26.
MunzarM, LevyS, RushR, AverbackP (2002) Clinical study of a urinary competitve ELISA for neural thread protein in Alzheimer disease. Neurol Clin Neurophysiol2002, 2–8.
27.
GoodmanI, GoldenG, FlitmanS, XieK, McConvilleM, LevyS, ZimmermanE, LebedevaZ, RichterR, MinagarA, AverbackP (2007) A multi-center blinded prospective study of urine neural thread protein measurements in patients with suspected Alzheimer’s disease. J Am Med Dir Assoc8, 21–30.
28.
LiY, KangM, WangH, JinH, WangX, GanW, ZhaoM, ZhaoX, WangR, HanY (2019) Urinary Alzheimer-associated neuronal thread protein is not elevated in patients with subjective cognitive decline and patients with depressive state. J Alzheimers Dis71, 1115–1123.
29.
KahlePJ, JakowecM, TeipelSJ, HampelH, PetzingerGM, Di MonteDA, SilverbergGD, MollerHJ, YesavageJA, TinklenbergJR, ShooterEM, MurphyGMJr (2000) Combined assessment of tau and neuronal thread protein in Alzheimer’s disease CSF. Neurology54, 1498–1504.
30.
ZhangQE, LingS, LiP, ZhangS, NgCH, UngvariGS, WangLJ, LeeSY, WangG, XiangYT (2018) The association between urinary Alzheimer-associated neuronal thread protein and cognitive impairment in late-life depression: A controlled pilot study. Int J Biol Sci14, 1497–1502.
31.
ZhangN, ZhangL, LiY, GordonML, CaiL, WangY, XingM, ChengY (2017) Urine AD7c-NTP predicts amyloid deposition and symptom of agitation in patients with Alzheimer’s disease and mild cognitive impairment. J Alzheimers Dis60, 87–95.
32.
WangC, CuiY, YangJ, ZhangJ, YuanD, WeiY, LiY, DuoY, LiS, ZhuW, ZhengL (2015) Combining serum and urine biomarkers in the early diagnosis of mild cognitive impairment that evolves into Alzheimer’s disease in patients with the apolipoprotein E 4 genotype. Biomarkers20, 84–88.
33.
BalmusIM, StrungaruSA, CiobicaA, NicoaraMN, DobrinR, PlavanG, StefanescuC (2017) Preliminary data on the interaction between some biometals and oxidative stress status in mild cognitive impairment and Alzheimer’s disease patients. Oxid Med Cell Longev2017, 7156928.
34.
SchuurM, HennemanP, van SwietenJC, ZillikensMC, de KoningI, JanssensAC, WittemanJC, AulchenkoYS, FrantsRR, OostraBA, van DijkKW, van DuijnCM (2010) Insulin-resistance and metabolic syndrome are related to executive function in women in a large family-based study. Eur J Epidemiol25, 561–568.
35.
EkbladLL, RinneJO, PuukkaPJ, LaineHK, AhtiluotoSE, SulkavaRO, ViitanenMH, JulaAM (2015) Insulin resistance is associated with poorer verbal fluency performance in women. Diabetologia58, 2545–2553.
36.
YoungSE, MainousAG3rd, CarnemollaM (2006) Hyperinsulinemia and cognitive decline in a middle-aged cohort. Diabetes Care29, 2688–2693.
37.
EkbladLL, RinneJO, PuukkaP, LaineH, AhtiluotoS, SulkavaR, ViitanenM, JulaA (2017) Insulin resistance predicts cognitive decline: An 11-year follow-up of a nationally representative adult population sample. Diabetes Care40, 751–758.
38.
BomfimTR, Forny-GermanoL, SathlerLB, Brito-MoreiraJ, HouzelJC, DeckerH, SilvermanMA, KaziH, MeloHM, McCleanPL, HolscherC, ArnoldSE, TalbotK, KleinWL, MunozDP, FerreiraST, De FeliceFG (2012) An anti-diabetes agent protects the mouse brain from defective insulin signaling caused by Alzheimer’s disease- associated Abeta oligomers. J Clin Invest122, 1339–1353.
39.
de la MonteSM, WandsJR (2004) Alzheimer-associated neuronal thread protein mediated cell death is linked to impaired insulin signaling. J Alzheimers Dis6, 231–242.
